In Brief: Sanofi Commits $20bn To US R&D And Manufacturing By 2030

US Almost Half Of Firm’s Q1 Revenue

Move by French major aligns with broader industry efforts to localize production amid political pressure, as Trump pushes to onshore manufacturing and hints at easing tariff threats.

Sanofi
Sanofi plans major new investments in US manufacturing and R&D • Source: Getty

Sanofi has joined the US investment bandwagon, announcing plans to invest at least $20bn in the country through 2030. The French group said the new funding will significantly increase its R&D spending there and direct billions of dollars toward domestic manufacturing.

Key Takeaways
  • Sanofi to invest $20bn in US R&D and manufacturing by 2030.

The company noted it is also preparing for the potential launch of numerous new first- or best-in-class medicines across multiple...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Manufacturing

More from Scrip

Pipeline Watch: Seven Approvals And Five Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Indegene Exec On DTP Distribution As A ‘Tactical Solution’, Feasibility Of MFN Model

 

Senior Indegene executive William Lobb talks about complexities of the direct-to-patient distribution model in the US and underlines that it isn’t a comprehensive healthcare fix. Feasibility of MFN pricing and why it may be “catastrophic” to the industry were some of the other topics discussed.

Quick Listen: Scrip’s Five Must-Know Things

 
• By 

In this week's episode: a look at the likely top drugs in 2030; Lilly CEO advocates US/Europe pricing rebalance; Insmed sees $5bn-plus market for Brinsupri; royalty deals go mainstream; Phase III win sets stage for Epkinly label expansion.